Skip to main content
For Healthcare Professionals

Reset all filters

91 - 100 of 102 results

Publications

Gathering our presentations, posters, abstracts, and publications, this educational resource offers materials across topics of interest in oncology. Explore the current topics below and revisit regularly to access the latest materials.

Infographic

Phase I trial of DLL3/CD3 IgG-like T-cell engager BI 764532 in patients with DLL3-positive tumors: patients with LCNEC-L
Phase I Trial of DLL3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients with DLL3-Positive Tumors: Patients with LCNEC-L
Author(s): Wermke et al.
LCNEC-L DLL3/CD3 TcE Infographic
Download
A Phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
A Phase Ia/Ib, dose-escalation/expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors
Author(s): Doi et al.
Solid tumors B7-H6/CD3 TcE, PD-1 inhibitor Infographic
Download
DAREON®-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)
DAREON®-8: A Phase I dose escalation/expansion trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) plus standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients with extensive-stage small cell lung carcinoma (ES-SCLC)
Author(s): Peters et al.
SCLC DLL3/CD3 TcE Infographic
Download
A Phase III trial of zongertinib (BI 1810631) compared with standard of care in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion™ LUNG-2
A Phase III trial of zongertinib (BI 1810631) compared with standard of care in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) harbouring HER2 tyrosine kinase domain mutations: Beamion™ LUNG-2
Author(s): Wu et al.
NSCLC HER2 TKI Infographic
Download
Beamion™ LUNG-1, a Phase Ia/b trial zongertinib (BI 1810631), in patients with NSCLC harbouring mutations in the HER2 gene: updated data
Beamion™ LUNG-1, a Phase Ia/Ib trial of zongertinib (BI 1810631) in patients with NSCLC harbouring mutations in the HER2 gene: updated data
Author(s): Wu et al.
Solid tumors, NSCLC HER2 TKI Infographic
Download
Beamion™ LUNG-1, an a Phase Ia/Ib trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC
Beamion™ LUNG-1, a Phase Ia/b trial of zongertinib (BI 1810631) in patients with solid tumors: focus on patients with HER2 mutation-positive NSCLC
Author(s): Yoh et al.
NSCLC, Solid tumors HER2 TKI Infographic
Download
A Phase Ib, open-label, dose escalation trial of the delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma.
A Phase Ib, open-label, dose escalation trial of the DLL3/CD3 IgG-like T-cell engager, BI 764532, in patients with DLL3-positive glioma
Author(s): van den Bent et al.
Solid tumor DLL3/CD3 TcE Infographic
Download
Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small cell lung cancer and other neuroendocrine carcinomas (NECs) expressing DLL3
Phase I dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T-cell engager) + ezabenlimab (anti-PD-1 antibody) in patients with small-cell lung cancer and other neuroendocrine carcinomas expressing DLL3
Author(s): Mazières et al.
SCLC, NEC/epNEC, LCNEC-L DLL3/CD3 TcE, PD-1 inhibitor Infographic
Download
Beamion™ LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data
Beamion™ LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor, zongertinib (BI 1810631) in patients with advanced solid tumours with HER2 mutations: latest data
Author(s): Ruiter et al.
Solid tumors HER2 TKI Infographic
Download
Phase I Beamion™ LUNG-1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: updated data
Phase I Beamion™ LUNG-1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations: updated data
Author(s): Heymach et al.
Solid tumor HER2 TKI Infographic
Download